Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

November 20, 2018

Caregivers Affected Significantly by Brain Cancer-Related Cognitive Dysfunction

Author(s):

Jessica Skarzynski

The cognitive dysfunction that patients with glioblastoma often face can compound these challenges and ultimately put extra stress on caregivers.

From taking care of everyday tasks like laundry and transportation to managing important health care decisions, caregivers of patients with cancer help their loved ones through the countless challenges that come with diagnosis and treatment.

However, the cognitive dysfunction that patients with glioblastoma often face can compound these challenges and ultimately put extra stress on caregivers, according to preliminary results of a recent study presented at the American Society of Clinical Oncology (ASCO) Palliative Care Symposium on November 16-17.

Glioblastoma is an aggressive type of brain cancer with a relatively poor prognosis and a high incidence of cognitive dysfunction in those it affects, including issues with memory, language problems and confusion. To better understand how this dysfunction impacts the burden that caregivers of patients with glioblastoma face, researchers from Utah, Florida, Ohio, Colorado, New Hampshire, California, North Carolina and Minnesota conducted a multisite study.

“The study includes a prospective survey of caregivers and a retrospective data extraction of clinical and treatment characteristics of patients whose caregiver agrees to take the survey,” lead author Trang H. Au, PharmD, MPH, faculty member at the Pharmacotherapy Outcomes Research Center (PORC) at the University of Utah, explained in an interview with CURE.

The 20- to 30-minute survey asks the caregivers about their demographics, the perceived cognitive state of their loved one and associated burden of care, such as the impact on caregiver emotions, daily life, health needs and work and finances.

The preliminary results presented at the symposium contained data from three sites: Duke University, the Huntsman Cancer Institute and the University of California Los Angeles. Survey responses from 54 caregivers and 48 patient-caregiver pairs were included.

Of patients, 74 percent were male, while 84 percent of caregivers were female. Patients were primarily unemployed and being treated for their initial diagnosis, while in the caregiver group, 42 percent of respondents were currently employed, and 32 percent received no additional help.

In the caregiver group, 48 percent of caregivers reported performing more than one caregiving task (such as meal preparation) before diagnosis compared to 97 percent after diagnosis.

When asked about the side effects of diagnosis and treatment, 90 percent of caregivers reported that their loved ones experienced memory problems in the past 14 days prior to filling out the survey.

“Caregivers were asked about specific manifestations of cognitive dysfunction and the degree to which these symptoms affected them on a daily basis,” Au explained. “For example, if a caregiver reported observing ‘memory problems,’ then they were asked how ‘trouble remembering recent events,’ ‘forgetting names of friends’ or ‘misplacing items’ affected the caregiver’s daily life.” Ultimately, 71 percent of caregivers said that their loved ones’ trouble with remembering recent events interfered with their daily life.

Next, on a scale from zero (none) to 10 (significant), caregivers were asked to rank how each instance of cognitive dysfunction affected various facets of their life, such as emotional health, general health, ability to work at their job and quality of life. A majority (60 percent) indicated a score of 5 or greater, while 23 percent indicated 8 or higher.

Only 23 percent of caregivers felt that enough is being done to understand their needs.

Given these preliminary results, enrollment in the study will continue at five sites through Spring 2019 in an effort to collect more data. According to Au, “Future directions for additional research include validating the survey, performing the study throughout community cancer centers in the U.S. and/or developing the survey into a longitudinal tool to measure caregiver burden over time in order to implement interventions to support caregivers.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of woman.
Image of two doctors with text.
Image of Dr. Merrell
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of woman.
Image of a woman with short brown hair, wearing glasses.
Image of a man with dark hair wearing a suit with a light blue tie.
Related Content
Advertisement
Two patients treated with Temferon have lived three years post-surgery: © stock.adobe.com.
July 2nd 2025

Temferon Linked to Long-Term Survival in Some With Glioblastoma

Spencer Feldman
Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers: © stock.adobe.com.
June 20th 2025

Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers

Spencer Feldman
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
The FDA granted fast track designation to RAD101 to improve detection of recurrent brain metastases: © stock.adobe.com.
June 13th 2025

FDA Grants Fast Track Designation to RAD101 in Brain Metastases

Spencer Feldman
The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients: © stock.adobe.com.
May 19th 2025

Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma

Spencer Feldman
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found.
Related Content
Advertisement
Two patients treated with Temferon have lived three years post-surgery: © stock.adobe.com.
July 2nd 2025

Temferon Linked to Long-Term Survival in Some With Glioblastoma

Spencer Feldman
Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers: © stock.adobe.com.
June 20th 2025

Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers

Spencer Feldman
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
The FDA granted fast track designation to RAD101 to improve detection of recurrent brain metastases: © stock.adobe.com.
June 13th 2025

FDA Grants Fast Track Designation to RAD101 in Brain Metastases

Spencer Feldman
The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients: © stock.adobe.com.
May 19th 2025

Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma

Spencer Feldman
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.